CIGB-814

N/A

Report date: 2024/12/26 17:40:28
NME

Base Information

Drug NameCIGB-814
Drug Alias NameJusvinzaCIGB-814CIGB-258
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionImmunomodulatorsHeat shock 70 kDa protein 14 modulators
TargetsHeat shock 70 kDa protein 14
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Arthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCubaMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCenter For Genetic Engineering And Biotechnology
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesCuban Center For Genetic Engineering And BiotechnologyPeking University People'S HospitalShandong Lukang Pharmaceutical Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Arthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A